Adoptive immunotherapy via CD4+ versus CD8+ T cells

Abstract

Abstract-The goal of cancer immunotherapy is to induce specific and durable antitumor immunity. Adoptive T cell therapy (ACT) has garnered wide interest, particularly in regard to strategies to improve T cell efficacy in trials. There are many types of T cells (and subsets) which can be selected for use in ACT. CD4+ T cells are critical for the regulation, activation and aid of host defense mechanisms and, importantly, for enhancing the function of tumor-specific CD8+ T cells. To date, much research in cancer immunotherapy has focused on CD8+ T cells, in melanoma and other cancers. Both CD4+ T cells and CD8+ T cells have been evaluated as ACT in mice and humans, and both are effective at eliciting antitumor responses. IL-17 producing CD4+ T cells are a new subset of CD4+ T cells to be evaluated in ACT models. This review discusses the benefits of adoptive immunotherapy mediated by CD8+ and CD4+ cells. It also discusses the various type of T cells, source of T cells, and ex vivo cytokine growth factors for augmenting clinical efficacy of ACT.

Cinnamomols A and B, Immunostimulative Diterpenoids with a New Carbon Skeleton from the Leaves of Cinnamomum cassia

“…There are two main types of T cells, CD4 + and CD8 + T cells, both of which are critical components of immunity. 16 However, one of the T cell subsets, CD4 + CD25 + Foxp3 + T cells (Tregs), dampens immune responses by inhibiting the function of effector CD4 + and CD8 + T cells. 17 We incubated cinnamomol A (1) with T cells to investigate which T cell populations are involved in immune modulation by 1.…”

“…T cells play an important role in regulating immune function because various T cell subsets carry out different duties to maintain immune balance. There are two main types of T cells, CD4 + and CD8 + T cells, both of which are critical components of immunity . However, one of the T cell subsets, CD4 + CD25 + Foxp3 + T cells (Tregs), dampens immune responses by inhibiting the function of effector CD4 + and CD8 + T cells .…”